PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

NYC Cancer Institute, New York

Columbia Medical Center, New York

UPMC Hillman Cancer Center, Pittsburgh

Inova Dwight and March Schar Cancer Institute, Fairfax

Virginia Cancer Specialists, Fairfax

Norton Cancer Institute, Louisville

University of Chicago, Chicago

Beacon Cancer Care, Coeur d'Alene

The Angeles Clinic and Research Institute, Los Angeles

City of Hope National Medical Center, Duarte

Oregon Health & Science Center, Portland

Providence Portland Medical Center, Portland

Multicare Institute for Research and Innovation, Spokane

Dana Farber Cancer Institute, Boston

Sunshine Coast University Private Hospital, Sunshine Coast

Ballarat Oncology and Haematology Services, Wendouree

The Netherlands Cancer Institute, Amsterdam

University Medical Center Groningen, Groningen

Asan Medical Center, Seoul

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

Severance Hospital Yonsei University Health System, Seoul

Hospital Clinic de Barcelona. Servicio Oncologia Medica, Barcelona

Hospital Universitario La Paz, Madrid

START- Madrid, Madrid

Clinica Universitaria de Navarra, Pamplona

ICO Hospitalet, Hospital Duran I Reynals, Barcelona